Literature DB >> 2201256

Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations.

E C Oldfield1, P D Garst, C Hostettler, M White, D Samuelson.   

Abstract

We conducted a randomized, double-blind trial of 1- versus 4-h infusions of amphotericin B to determine whether there was any difference in infusion-related toxicity. A total of 128 maintenance infusions in 12 patients were studied; 62 were randomized to 1-h infusions (group A) and 66 were randomized to 4-h infusions (group B). We found no significant differences between patients in groups A and B in mean temperature, pulse, or systolic or diastolic blood pressure measured during the infusions. At a significant level of 0.05, the power to detect a mean difference in temperature of 2 degrees C, a pulse difference of 20 beats per min, a decrease in diastolic blood pressure of 10 mm Hg, or a decrease in systolic blood pressure of 20 mm Hg was 0.95. Rigors and chills were noted in 15 of 62 (24.1%) infusions in group A patients and 12 of 66 (18.1%) infusions in group B patients (P = 0.40). Meperidine was required because of severe persistent rigors in 6 of 62 (9.6%) infusions in group A patients and 6 of 66 (8.9%) infusions in group B patients (P = 0.91). An increase in temperature was noted in five (8%) of the group A infusions and seven (10.6%) of the group B infusions (P = 0.63). The mean time to onset of rigors, an increase in temperature, and an increase in pulse occurred significantly earlier in group A than in group B patients (P = 0.02 for all comparisons). We conclude that there is no difference in the incidence or severity of the infusion-related toxicity of amphotericin B with a 1-h infusion rate compared with a 4-h infusion rate. However, the onset of infusion-related toxicity occurs significantly earlier with a 1-h infusion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201256      PMCID: PMC175990          DOI: 10.1128/AAC.34.7.1402

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  A guide to production, care and use of laboratory animals. An annotated bibliography. 4. Breeding programs: design and operation of production colony.

Authors:  J S CASS; I R CAMPBELL; L LANGE
Journal:  Fed Proc       Date:  1963 Mar-Apr

2.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  Effect of infusion rate on amphotericin B-associated febrile reactions.

Authors:  J D Cleary; D Weisdorf; C V Fletcher
Journal:  Drug Intell Clin Pharm       Date:  1988-10

4.  CKryptococcosis treated by rapid infusion of amphotericin B.

Authors:  R A Tarala; J D Smith
Journal:  Br Med J       Date:  1980-07-05

5.  Risk factors of ventricular fibrillation during rapid amphotericin B infusion.

Authors:  P C Craven; D H Gremillion
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

6.  Effect of rapid intravenous infusion on serum concentrations of amphotericin B.

Authors:  B T Fields; J H Bates; R S Abernathy
Journal:  Appl Microbiol       Date:  1971-10

7.  Amphotericin B fever in rabbits.

Authors:  J C Arroyo
Journal:  Life Sci       Date:  1984-03-26       Impact factor: 5.037

8.  Retrospective review of amphotericin B use in a tertiary-care medical center.

Authors:  M H Gross; W W Pickard; J R Perfect
Journal:  Am J Hosp Pharm       Date:  1987-06

9.  Antifungal agents used for deep-seated mycotic infections.

Authors:  C L Terrell; P E Hermans
Journal:  Mayo Clin Proc       Date:  1987-12       Impact factor: 7.616

10.  Transient asystole associated with amphotericin B infusion.

Authors:  H J DeMonaco; B McGovern
Journal:  Drug Intell Clin Pharm       Date:  1983 Jul-Aug
  10 in total
  9 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

2.  Effect of infusion rates on toxicity of amphotericin B.

Authors:  H D Davies; A Matlow; S King; G Koren
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

3.  Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B.

Authors:  M E Ellis; A A al-Hokail; H M Clink; M A Padmos; P Ernst; D G Spence; W N Tharpe; V F Hillier
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Amphotericin B in lipid emulsion: stability, compatibility, and in vitro antifungal activity.

Authors:  S Walker; S A Tailor; M Lee; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

5.  Controlled pilot study of rapid amphotericin B infusions.

Authors:  H Dele Davies; S M King; J Doyle; A Matlow; G Koren; R Hamilton; C Portwine
Journal:  Arch Dis Child       Date:  1997-02       Impact factor: 3.791

6.  Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial.

Authors:  U Eriksson; B Seifert; A Schaffner
Journal:  BMJ       Date:  2001-03-10

Review 7.  Systemic antifungal agents.

Authors:  W Abuhammour; E Habte-Gabr
Journal:  Indian J Pediatr       Date:  2001-07       Impact factor: 1.967

8.  Risk of ventricular dysrhythmias during 1-hour infusions of amphotericin B in patients with preserved renal function.

Authors:  W A Bowler; P J Weiss; H E Hill; K A Hoffmeister; R P Fleck; A R Blacky; E C Oldfield
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.

Authors:  Matthew E Falagas; Drosos E Karageorgopoulos; Giannoula S Tansarli
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.